sintilimab
{{short description|Medication to treat Hodgkin's disease}}
{{cs1 config|name-list-style=vanc}}
{{COI|date=December 2021}}
{{Infobox drug
| type = mab
| image =
| alt =
| mab_type =
| source =
| target =
| pronounce =
| tradename =
| Drugs.com =
| MedlinePlus =
| pregnancy_AU =
| pregnancy_US =
| pregnancy_category=
| legal_AU =
| legal_AU_comment =
| legal_BR =
| legal_BR_comment =
| legal_CA =
| legal_UK =
| legal_US =
| legal_UN =
| legal_NZ =
| legal_status =
| routes_of_administration =
| bioavailability =
| protein_bound =
| metabolism =
| metabolites =
| onset =
| elimination_half-life =
| duration_of_action=
| excretion =
| CAS_number = 2072873-06-2
| ATC_prefix =
| ATC_suffix =
| PubChem =
| DrugBank =
| KEGG = D12119
| UNII = 8FU7FQ8UPK
| synonyms = Anti-PD-1 monoclonal antibody IBI308{{cite web |url=https://www.cancer.gov/publications/dictionaries/cancer-drug/def/anti-pdcd1-monoclonal-antibody-ibi308|title=anti-PD-1 monoclonal antibody IBI308 |date=2011-02-02 | work = NCI Drug Dictionary |publisher=National Cancer Institute }}
}}
Sintilimab, sold under the brand Tyvyt among others, is a medication used to treat Hodgkin's disease,{{cite web |url=https://www.reuters.com/article/us-innovent-biologics-ipo/chinas-innovent-prices-hk-ipo-near-top-end-raises-421-million-sources-idUSKCN1MY06Q|title=Antibody Drug Conjugates Market Growth Forecast Analysis by Manufacturers, Regions, Type and Application to 2026|date=October 24, 2018|publisher=Reuters}} and has been approved in China.{{cite web |url=https://www.asianscientist.com/2019/01/pharma/innovent-eli-lilly-sintilimab-tyvyt-hodgkins-lymphoma/|title=NMPA Approves Tyvyt For Hodgkin's lymphoma Read |date=January 9, 2019|publisher=Asian Scientist Magazine }}
It is a fully human IgG4 monoclonal antibody{{cite journal | vauthors = Ying K, Xu N, Jiang H, Liu Y, Zhou H, Wang S |url=https://www.jto.org/article/S1556-0864(18)33216-7/fulltext |title= OA08 Efficacy and Safety of Sintilimab Combined with 1st Line Chemotherapy in Advanced Squamous Cell Non-small Cell Lung Cancer |journal=Journal of Thoracic Oncology |access-date=Dec 1, 2018|doi=10.1016/j.jtho.2018.10.018|year=2018 |volume=13 |issue=12 |pages=S1047 |doi-access=free }} that binds to programmed cell death protein 1.{{cite journal | vauthors = Hoy SM | title = Sintilimab: First Global Approval | journal = Drugs | volume = 79 | issue = 3 | pages = 341–346 | date = February 2019 | pmid = 30742278 | doi = 10.1007/s40265-019-1066-z | s2cid = 59945274 }}
It was jointly developed by Innovent Biologics{{cite web |url= https://www.sec.gov/Archives/edgar/data/1648257/000164825718000075/c257-20181220ex991ad34d7.htm |title=Chi-Med Announces Amendment to the 2013 License & Collaboration Agreement on Fruquintinib with Eli Lilly and Company|date=December 20, 2018|publisher=SEC.gov}} and Eli Lilly.{{cite web |url=https://adisinsight.springer.com/drugs/800048000 |title= Sintilimab - Eli Lilly/Innovent Biologics | work = Adis Insight |date=28 March 2019 |publisher= Springer Nature Switzerland AG }}
Medical uses
Sintilimab is medication that is indicated for the treatment of relapsed or refractory classical Hodgkin's lymphoma after failure of at least second-line systemic chemotherapy.
Side effects
Common side effects include fever, thyroid dysfunction, elevation of liver enzymes, and lung inflammation.{{cite conference | conference = 2018 ASCO Annual Meeting |url=https://meetinglibrary.asco.org/record/159464/abstract|title=A first-in-human phase 1a trial of sintilimab (IBI308)|date=12 October 2019|publisher=American Society of Clinical Oncology}}
Research
Currently, more than 20 clinical trials are ongoing to evaluate the anti-tumor effect of sintilimab injection, either as monotherapy or in combination with other agents, on a variety of solid tumors.{{cite press release |url= https://www.prnewswire.com/news-releases/innovent-organized-a-forum-discussing-the-pending-launch-of-its-anti-pd-1-tyvyt-sintilimab-injection-as-part-of-the-national-mega-innovation-program-in-beijing-300800243.html |title=Innovent Organized a Forum Discussing the Pending Launch of its Anti PD-1 Tyvyt® (Sintilimab injection)|access-date=Feb 22, 2019 | author = Innovent Biologics, Inc. |work= PR NewsWire }} In January 2019, the result of the registration trial of sintilimab in people with refractory or relapsed classical Hodgkin's lymphoma was published.{{cite journal | vauthors = Ansell SM | title = Sintilimab: another effective immune checkpoint inhibitor in classical Hodgkin lymphoma | journal = The Lancet. Haematology | volume = 6 | issue = 1 | pages = e2–e3 | date = January 2019 | pmid = 30612711 | doi = 10.1016/S2352-3026(18)30210-2 | s2cid = 58561198 }}